EUVIMEDEUVIMED entdecken
Crossref

Pyroptosis‐Mediated Antitumor Activity of Cinobufagin in Non‐Small Cell Lung Cancer

Ying Chen, Feng Hu, Jiahuan Lu iD, Tengteng Zhu, Yajie Zheng, Yangyang Li, Jinwei Li, Kai Sheng, Feng Luo

Clinical and Experimental Pharmacology and Physiology · 2025

DOI: 10.1111/1440-1681.70055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, 2025. Verfasst von Ying Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Pyroptosis, Bufanolides, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Shanghai Changning District Committee of Science and Technology, Shanghai Changning District Health Commission Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aims to investigate the therapeutic efficacy and molecular mechanism of cinobufagin in non‐small cell lung cancer (NSCLC) via pyroptosis induction. Bronchial epithelial cells and NSCLC cell lines were treated with gradient concentrations of cinobufagin. Cell viability was evaluated using Cell Counting Kit‐8 (CCK‐8) assay. RNA‐sequencing was performed to identify differentially expressed genes. Lactate dehydrogenase (LDH) release was measured via cytotoxicity detection kit. Pyroptotic morphological changes were observed by transmission electron microscopy. Western blotting analysed expression levels of pyroptosis‐related proteins. In vivo efficacy was validated in nude mouse xenograft models. Immunohistochemistry evaluated tumour pyroptosis markers, whilst flow cytometry analysed tumour‐infiltrating CD8 + T cells and natural killer (NK) cells. Cinobufagin demonstrated selective cytotoxicity against NSCLC cells with minimal toxicity to normal bronchial epithelium. RNA‐seq analysis revealed significant enrichment of pyroptosis‐related pathways. Functional experiments confirmed cinobufagin‐induced LDH release, characteristic pyroptotic morphological changes and upregulation of cleaved caspase‐3 and Gasdermin E (GSDME)‐NT in NSCLC cells. In xenograft models, cinobufagin treatment reduced tumour volume compared to controls. Mechanistically, this was associated with enhanced caspase‐3 activation and GSDME‐NT accumulation in tumour tissues. Notably, cinobufagin treatment significantly increased NK cell infiltration and activity. Cinobufagin exerts antitumor effects in NSCLC through caspase‐3/GSDME‐mediated pyroptosis induction, accompanied by immune microenvironment modulation. These findings provide preclinical evidence for cinobufagin as a potential therapeutic agent targeting pyroptosis in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyroptosisBufanolidesLung NeoplasmsCarcinoma, Non-Small-Cell LungAntineoplastic AgentsHumansAnimalsMiceCell Line, TumorMice, NudeXenograft Model Antitumor AssaysCell Survival

Stichwörter der Autor:innen

GSDMEcaspase‐3cinobufaginnon‐small cell lung cancerpyroptosis

Substanzen

BufanolidescinobufaginAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Radiation Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Respiratory and Critical Care Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Geriatrics, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and Faculty of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Chongming Hospital Affiliated to Shanghai University of Medicine and Health Sciences (Xinhua Hospital Chongming Branch), Shanghai, China.

ORCID-Profile: Jiahuan Lu

Förderung

  • Shanghai Changning District Committee of Science and Technology
  • Shanghai Changning District Health Commission Project

Zitieren

APA

Chen, Y., Hu, F., Lu, J., Zhu, T., Zheng, Y., Li, Y., Li, J., Sheng, K., & Luo, F. (2025). Pyroptosis‐Mediated Antitumor Activity of Cinobufagin in Non‐Small Cell Lung Cancer. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.70055

Vancouver

Chen Y, Hu F, Lu J, Zhu T, Zheng Y, Li Y, et al. Pyroptosis‐Mediated Antitumor Activity of Cinobufagin in Non‐Small Cell Lung Cancer. Clinical and Experimental Pharmacology and Physiology. 2025. doi:10.1111/1440-1681.70055

BibTeX
@article{Chen2025,
  author = {Chen, Ying and Hu, Feng and Lu, Jiahuan and Zhu, Tengteng and Zheng, Yajie and Li, Yangyang and Li, Jinwei and Sheng, Kai and Luo, Feng},
  title = {Pyroptosis‐Mediated Antitumor Activity of Cinobufagin in Non‐Small Cell Lung Cancer},
  journal = {Clinical and Experimental Pharmacology and Physiology},
  year = {2025},
  doi = {10.1111/1440-1681.70055}
}
Kostenlos starten →